NeuroSense Therapeutics Ltd., a foreign private issuer, has announced the completion of its 18-month dosing schedule for the PARADIGM Phase 2b ALS clinical trial as of October 2024. The company has reached a significant milestone with the Last Patient Last Visit and is preparing to report the top-line clinical results from the full study in early December 2024. This information was disclosed in their Report on Form 6-K filed with the United States Securities and Exchange Commission (SEC). The report is also incorporated by reference into the company's existing Registration Statements on Form S-8 and Form F-3. NeuroSense Therapeutics has cautioned that the report contains forward-looking statements which are subject to risks and uncertainties, and actual results may differ materially...Show More

NeuroSense Therapeutics Ltd., a foreign private issuer, has announced the completion of its 18-month dosing schedule for the PARADIGM Phase 2b ALS clinical trial as of October 2024. The company has reached a significant milestone with the Last Patient Last Visit and is preparing to report the top-line clinical results from the full study in early December 2024. This information was disclosed in their Report on Form 6-K filed with the United States Securities and Exchange Commission (SEC). The report is also incorporated by reference into the company's existing Registration Statements on Form S-8 and Form F-3. NeuroSense Therapeutics has cautioned that the report contains forward-looking statements which are subject to risks and uncertainties, and actual results may differ materially from those anticipated. These statements include anticipated timelines for reporting clinical trial results and discussions with regulatory authorities such as the FDA and Health Canada. The company has outlined potential risks in its filings, including delays in reporting results, unexpected R&D costs, and the efficacy and safety of their product candidate, PrimeC. The company's latest Annual Report on Form 20-F filed with the SEC on April 4, 2024, contains a detailed discussion of these risk factors.